Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.
Adolescents and young adults
Colorectal cancer
Molecular profiling
Tumor sidedness
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
22
07
2019
accepted:
13
09
2019
pubmed:
19
12
2019
medline:
22
6
2021
entrez:
19
12
2019
Statut:
ppublish
Résumé
The incidence of colorectal cancer (CRC), particularly left-sided tumors (LT), in adolescents and young adults (AYA) is rising. Epigenetic events appear to play an important role in tumorigenesis and cancer progression, especially in younger patients. We compared molecular features of LT to right-sided tumors (RT) in AYA. A total of 246 LT and 56 RT were identified in a cohort of 612 AYA with primary CRC. Tumors were examined by next-generation sequencing (NGS), protein expression, and gene amplification. Tumor mutational burden (TMB) and microsatellite instability (MSI) were determined based on NGS data. RT showed higher mutation rates compared with LT in several genes including BRAF (10.3% vs. 2.8%), KRAS (64.1% vs. 45.5%), PIK3CA (27% vs. 11.2%), and RNF43 (24.2% vs. 2.9%). Notably, additional mutations in distinct genes involved in histone modification and chromatin remodeling, as well as genes associated with DNA repair and cancer-predisposing syndromes, were characteristic of RT; most frequently KMT2D (27.8% vs. 3.4%), ARID1A (53.3% vs. 21.4%), MSH6 (11.1% vs. 2.3%), MLH1 (10.5% vs. 2.3%), MSH2 (10.5% vs. 1.2%), POLE (5.9% vs. 0.6%), PTEN (10.8% vs. 2.3%), and BRCA1 (5.4% vs. 0.6%). MSI was seen in 20.8% of RT versus 4.8% of LT. RT had a higher frequency of TMB-high regardless of MSI status. Molecular profiling of AYA CRC revealed different molecular characteristics in RT versus LT. Epigenetic mechanisms and alteration in DNA repair genes warrant further investigation and may be a promising treatment target for CRC in AYA. Colorectal cancer (CRC) in adolescents and young adults (AYA) comprises a distinct entity with different clinicopathologic features and prognosis compared with older patients. Molecular profiling of right- and left-sided tumors in AYA is needed to gain novel insight into CRC biology and to tailor targeted treatment in this age group. This study found that right- and left-sided CRC show distinct molecular features in AYA, overall and in subgroups based on microsatellite instability status. Alterations in DNA double-strand break repair and homologous recombination repair, as well as epigenetic mechanisms, appear to play a critical role. The present molecular profiling data may support the development of personalized treatment strategies in the AYA population.
Sections du résumé
BACKGROUND
The incidence of colorectal cancer (CRC), particularly left-sided tumors (LT), in adolescents and young adults (AYA) is rising. Epigenetic events appear to play an important role in tumorigenesis and cancer progression, especially in younger patients. We compared molecular features of LT to right-sided tumors (RT) in AYA.
MATERIALS AND METHODS
A total of 246 LT and 56 RT were identified in a cohort of 612 AYA with primary CRC. Tumors were examined by next-generation sequencing (NGS), protein expression, and gene amplification. Tumor mutational burden (TMB) and microsatellite instability (MSI) were determined based on NGS data.
RESULTS
RT showed higher mutation rates compared with LT in several genes including BRAF (10.3% vs. 2.8%), KRAS (64.1% vs. 45.5%), PIK3CA (27% vs. 11.2%), and RNF43 (24.2% vs. 2.9%). Notably, additional mutations in distinct genes involved in histone modification and chromatin remodeling, as well as genes associated with DNA repair and cancer-predisposing syndromes, were characteristic of RT; most frequently KMT2D (27.8% vs. 3.4%), ARID1A (53.3% vs. 21.4%), MSH6 (11.1% vs. 2.3%), MLH1 (10.5% vs. 2.3%), MSH2 (10.5% vs. 1.2%), POLE (5.9% vs. 0.6%), PTEN (10.8% vs. 2.3%), and BRCA1 (5.4% vs. 0.6%). MSI was seen in 20.8% of RT versus 4.8% of LT. RT had a higher frequency of TMB-high regardless of MSI status.
CONCLUSION
Molecular profiling of AYA CRC revealed different molecular characteristics in RT versus LT. Epigenetic mechanisms and alteration in DNA repair genes warrant further investigation and may be a promising treatment target for CRC in AYA.
IMPLICATIONS FOR PRACTICE
Colorectal cancer (CRC) in adolescents and young adults (AYA) comprises a distinct entity with different clinicopathologic features and prognosis compared with older patients. Molecular profiling of right- and left-sided tumors in AYA is needed to gain novel insight into CRC biology and to tailor targeted treatment in this age group. This study found that right- and left-sided CRC show distinct molecular features in AYA, overall and in subgroups based on microsatellite instability status. Alterations in DNA double-strand break repair and homologous recombination repair, as well as epigenetic mechanisms, appear to play a critical role. The present molecular profiling data may support the development of personalized treatment strategies in the AYA population.
Identifiants
pubmed: 31848314
pii: theoncologist.2019-0552
doi: 10.1634/theoncologist.2019-0552
pmc: PMC7216442
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
404-413Subventions
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Informations de copyright
© AlphaMed Press 2019.
Références
Oncologist. 2019 Mar;24(3):319-326
pubmed: 30018131
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Lancet Oncol. 2017 Dec;18(12):1579-1589
pubmed: 29111259
Cancer Discov. 2018 Jun;8(6):730-749
pubmed: 29510987
Medicine (Baltimore). 2015 Sep;94(35):e1402
pubmed: 26334895
JAMA Surg. 2015 Jan;150(1):17-22
pubmed: 25372703
Nat Genet. 2014 Dec;46(12):1264-6
pubmed: 25344691
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer. 2016 Mar 15;122(6):929-34
pubmed: 26808454
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
Ann Oncol. 2017 Aug 01;28(8):1713-1729
pubmed: 28407110
Gastroenterol Res Pract. 2015;2015:132190
pubmed: 26557847
Therap Adv Gastroenterol. 2017 Jan;10(1):114-131
pubmed: 28286564
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
J Pathol. 2013 Jun;230(2):148-53
pubmed: 23447401
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
JAMA Oncol. 2017 Apr 01;3(4):464-471
pubmed: 27978560
Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3
pubmed: 29627309
Eur J Cancer. 2017 Nov;86:266-274
pubmed: 29055842
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54
pubmed: 23847203
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
Cancer. 2016 Sep 15;122(18):2828-35
pubmed: 27244218
Oncology (Williston Park). 2017 May 15;31(5):381-9
pubmed: 28516436
J Natl Compr Canc Netw. 2017 Mar;15(3):411-419
pubmed: 28275039
PLoS One. 2012;7(9):e45357
pubmed: 23049789
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
Nature. 2015 Oct 8;526(7572):263-7
pubmed: 26416732
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216
pubmed: 28404093
J Clin Oncol. 2015 Nov 1;33(31):3544-9
pubmed: 26195711
World J Gastroenterol. 2016 Feb 7;22(5):1736-44
pubmed: 26855533
Mol Immunol. 2017 Jul;87:227-239
pubmed: 28511092
Am J Hum Genet. 2018 Mar 1;102(3):401-414
pubmed: 29478780
J Natl Cancer Inst. 2016 Jan;108(1):
pubmed: 26719881
World J Gastroenterol. 2014 Sep 21;20(35):12420-30
pubmed: 25253942
PLoS One. 2014 Jul 08;9(7):e102004
pubmed: 25003760
Transl Oncol. 2017 Apr;10(2):190-196
pubmed: 28182994
PLoS One. 2014 Aug 01;9(8):e103159
pubmed: 25083765
Oncotarget. 2017 Sep 21;8(49):86356-86368
pubmed: 29156800
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Clin Colorectal Cancer. 2016 Mar;15(1):32-6
pubmed: 26341410
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Mol Cancer Res. 2018 Mar;16(3):476-485
pubmed: 29187560
Eur J Cancer. 2017 Oct;84:69-80
pubmed: 28787661
Cancer Cell. 2018 Jan 8;33(1):125-136.e3
pubmed: 29316426
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Cancer. 2018 Mar 1;124(5):1070-1082
pubmed: 29194591